UpStreAm doxycycline in ST-eLeVation myocArdial infarction: targetinG infarct hEaling and ModulatIon (SALVAGE-MI trial)
- 26 December 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 12 (3) , 143-152
Abstract
Aims: Experimental studies demonstrate protective effects of doxycycline on myocardial ischaemia-reperfusion injury. The trial investigated whether doxycycline administered prior to reperfusion in patients presenting with ST-elevation myocardial infarction (STEMI) reduces infarct size (IS) and ameliorates adverse left ventricular (LV) remodelling.Methods and results: In this randomized, double-blind, placebo-controlled trial, patients presenting with STEMI undergoing primary percutaneous coronary intervention (PPCI) were randomized to either intravenous doxycycline or placebo prior to reperfusion followed by 7 days of oral doxycycline or placebo. The primary outcome was final IS adjusted for area-at-risk (fIS/AAR) measured on two cardiac magnetic resonance scans ∼6 months apart. Of 103 participants, 50 were randomized to doxycycline and 53 to placebo and were matched for age (59 ± 12 vs. 60 ± 10 years), male sex (92% vs. 79%), diabetes mellitus (26% vs. 11%) and left anterior descending artery occlusion (50% vs. 49%), all P > 0.05. Patients treated with doxycycline had a trend for larger fIS/AAR [0.79 (0.5–0.9) vs. 0.61 (0.47–0.76), P = 0.06], larger fIS at 6 months [18.8% (12–26) vs. 13.6% (11–21), P = 0.08], but similar acute IS [21.7% (17–34) vs. 19.4% (14–27), P = 0.19] and AAR [26% (20–36) vs. 24.7% (16–31), P = 0.22] compared with placebo. Doxycycline did not ameliorate adverse LV remodelling [%Δend-diastolic volume index, 1.1% (−3.8–8.4) vs. −1.34% (−6.1–5.8), P = 0.42] and was independently associated with larger fIS (regression coefficient = 0.175, P = 0.03).Conclusion: Doxycycline prior to PPCI neither reduced IS acutely or at six months nor attenuated adverse LV remodelling. These data raise safety concerns regarding doxycycline use in STEMI for infarct modulation and healing.Keywords
Funding Information
- Alfred Health Research (AS16001)
- Australian National Health Foundation (102336)
- National Health and Medical Research Council
- National Heart Foundation Fellowship.
This publication has 32 references indexed in Scilit:
- Effect of Iron Chelation on Myocardial Infarct Size and Oxidative Stress in ST-Elevation–Myocardial InfarctionCirculation: Cardiovascular Interventions, 2012
- Tetracycline compounds with non-antimicrobial organ protective properties: Possible mechanisms of actionPharmacological Research, 2011
- Translating novel strategies for cardioprotection: the Hatter Workshop RecommendationsBasic Research in Cardiology, 2010
- Protective action of doxycycline against diabetic cardiomyopathy in ratsBritish Journal of Pharmacology, 2008
- Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imagingEuropean Heart Journal, 2007
- Effects of Selective Matrix Metalloproteinase Inhibitor (PG-116800) to Prevent Ventricular Remodeling After Myocardial InfarctionJACC, 2006
- Postconditioning the Human HeartCirculation, 2005
- Matrix Metalloproteinase-9 Is Required for Adequate Angiogenic Revascularization of Ischemic TissuesCirculation Research, 2004
- Early Short-Term Treatment With Doxycycline Modulates Postinfarction Left Ventricular RemodelingCirculation, 2003
- Ventricular Remodeling After Infarction and the Extracellular Collagen MatrixCirculation, 2003